MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q3
hinzugefügt 07.11.2022
AVEO Pharmaceuticals Betriebsaufwand 2011-2026 | AVEO
Betriebsaufwand Jährlich AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 44.9 M | 29.2 M | 31.4 M | 34.3 M | 31.9 M | 27.1 M | 56.8 M | 97.2 M | 128 M | 131 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 131 M | 27.1 M | 61.2 M |
Betriebsaufwand Vierteljährlich AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 24.4 M | 22.6 M | 21 M | 13.6 M | 11.7 M | 8.16 M | 11.5 M | 7.4 M | 6.87 M | 5.6 M | 9.31 M | 7.83 M | 7.88 M | 7 M | 8.06 M | 10.2 M | 6.77 M | 9.18 M | 10.3 M | - | 6.58 M | 7.34 M | 8.44 M | - | 6.69 M | 4.76 M | 10.3 M | 11.8 M | 15 M | 19.3 M | 21.2 M | 16.4 M | 23.9 M | 31.4 M | 33.5 M | 36.1 M | 30.4 M | 30.6 M | 33.8 M | 25.5 M | 26.7 M | 31.4 M | 47.2 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 47.2 M | 4.76 M | 16.8 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 8.97 | 2.87 % | $ 88.7 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.66 | - | $ 8.81 B |  Australia |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
51.4 M | $ 3.21 | 3.05 % | $ 274 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 95.59 | -1.15 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
106 M | $ 4.68 | 4.23 % | $ 746 M | Britain |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.27 | 2.19 % | $ 329 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.46 | 0.47 % | $ 1 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.49 | 1.35 % | $ 383 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.03 | 3.77 % | $ 4.99 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.19 | - | $ 448 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 24.98 | 3.55 % | $ 3.18 B | USA |
 |
Chimerix
CMRX
|
93.4 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
110 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 32.74 | 0.46 % | $ 2.17 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.48 | 0.46 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
177 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
16 M | $ 2.44 | -2.99 % | $ 1.08 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
47.8 M | - | - | $ 1.2 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |